/
Infectious Disease
Chronic Hepatitis B Virus Infection
13
Pipeline Programs↗
8
Active Trials↗
20
Companies Involved↗
Chronic Hepatitis B Virus Infection is an emerging landscape with 13 programs across 20 companies. The most active players are Vir Biotechnology, Inc., Suzhou HepaThera Biotech Co., Ltd., GSK.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 27
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
82%
Small molecule
9 of 11 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 13 pipeline programs.
Analysis
Trial Status
46
clinical trials
Completed23 · 50%
Terminated12 · 26%
Active, not recruiting5 · 11%
Unknown status3 · 7%
Recruiting2 · 4%
Not yet recruiting1 · 2%
Clinical Trials
Trial Activity
46 trials
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)